Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.69 |
| ▸ | CCR1 | P32246 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10117149 | 0.88 | RXFP1 (0.71) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL10120633 | 0.86 | CCR1 (0.65) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL10120635 | 0.86 | CCR1 (0.69) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL10120637 | 0.84 | CCR1 (0.63) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL12336305 | 0.84 | RXFP1 (0.60) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL10117466 | 0.84 | ALOX15 (0.57) | RXFP1CCR1KDM4EP2RX3MEN1 | |
| SCHEMBL2232358 | 0.82 | CCR1 (0.59) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL6776725 | 0.82 | RXFP1 (1.00) | RXFP1CCR1KDM4EHPGDMEN1 | |
| SCHEMBL10117296 | 0.81 | RXFP1 (0.79) | RXFP1CCR1KDM4EHPGDP2RX3 | |
| SCHEMBL6782671 | 0.81 | CCR1 (1.00) | RXFP1CCR1KDM4EHPGDP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497263-B2 | Pyrrolinone derivative and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2013-07-30 | — | — | US | disclosed |
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KAI HIROYUKI (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010199-A1 | NOVEL PYRROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | P2RX3, P2RX2, P2RX1 | RXFP1 31/4885CCR1 1184/4885KDM4E 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.